We are live on
!
Find out more
SCM
Sarissa Capital Management Portfolio holdings
AUM
$158M
1-Year Est. Return
103.7%
This Fund
S&P 500
This Quarter
Est. Return
+22.19%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$253M
AUM Growth
-$110M
(-30%)
Cap. Flow
-$149M
Cap. Flow
% of AUM
-58.81%
Top 10 Holdings %
Top 10 Hldgs %
99.76%
Holding
12
New
1
Increased
1
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
+$7.63M |
| 2 |
Innoviva
INVA
|
+$5.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$160M |
| 2 |
ADXS
Advaxis Inc
ADXS
|
+$1.39M |
| 3 |
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
|
+$496K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDCO
1
DELISTED
Medicines Co
MDCO
| $85.7M | 33.86% |
1,752,000
| – | – |
|
2
Biogen
BIIB
$30B
| $84.8M | 33.49% |
310,000
| – | – |
|
|
3
Innoviva
INVA
$1.55B
| $47.4M | 18.72% |
3,425,000
+450,000
| +15% | +$5.3M |
|
|
NVLN
4
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $11M | 4.35% |
1,025,000
| – | – |
|
|
BIVV
5
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $8.44M | 3.34% |
+155,000
| New | +$7.63M |
|
|
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $5.85M | 2.31% |
360,000
| – | – |
|
|
SEEL
7
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $3.06M | 1.21% |
13
| – | – |
|
|
VVUS
8
DELISTED
Vivus Inc
VVUS
| $2.88M | 1.14% |
257,394
| – | – |
|
|
ADXS
9
DELISTED
Advaxis Inc
ADXS
| $2.77M | 1.1% |
22,612
-10,721
| -32% | -$1.39M |
|
10
AbbVie
ABBV
$443B
| $651K | 0.26% |
10,000
| – | – |
|
|
AVEO
11
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $598K | 0.24% |
101,362
-68,638
| -40% | -$496K |
|
|
ARIA
12
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| – | – |
-12,850,000
| Closed | -$160M |
|
Similar funds
4A
DAM
PCP
CF
HEM
SF
AC
EP
Sarissa Capital Management's Q1 2017 Portfolio in Review
As of Q1 2017, Sarissa Capital Management held 12 positions worth $253M, down 30% from $363M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Sarissa Capital Management withdrew a net $149M in Q1 2017, closing 1 position and reducing 2 holdings. Its most notable exit was Ariad Pharmaceuticals Inc, an estimated $160M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 84% a quarter earlier.
Against the trend, Sarissa Capital Management opened a new position in Bioverativ Inc. Common Stock worth $8.44M.
- Sarissa Capital Management's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 155,000 shares worth $8.44M.
- Sarissa Capital Management added most to Innoviva in Q1 2017, an estimated $5.3M increase.
- Sarissa Capital Management's biggest Q1 2017 reduction was Advaxis Inc, cutting an estimated $1.39M.
- Sarissa Capital Management fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $160M.
- Sarissa Capital Management's ten largest holdings make up 100% of its $253M portfolio in Q1 2017.
- Sarissa Capital Management opened 1 new position and closed 1 in Q1 2017.
- Sarissa Capital Management's portfolio value fell 30% quarter-over-quarter to $253M.
Based on Sarissa Capital Management's 13F filing for Q1 2017, filed 15 May 2017.